Skip to main content
. 2019 Jan 15;6(2):355–363. doi: 10.1002/acn3.711

Figure 1.

Figure 1

Percentages (A, B, C) and absolute cell counts (D, E, F) of terminally differentiated (TD) CD4+ T cells (A, D), plasmablasts (B, E) and PD‐L1+ monocytes (C, F) obtained before (basal) and at 6 months of teriflunomide treatment (n = 55). Percentages are referred to total peripheral blood mononuclear cells (PBMC).